In previous reports, ALK rearrangements in early-stage NSCLC were associated with a trend towards poorer outcomes compared with other clinically relevant genomic subsets (e.g., EGFR, KRAS mutation). This evidence concerns the gene ALK and non-small cell lung carcinoma.